ストックスクリーナーアプリを入手
15.91
2.03%
-0.33
前日終値:
$16.24
開ける：
$16.27
24時間の取引高:
1.06M
Relative Volume:
0.47
時価総額：
$2.43B
収益：
$205.22M
当期純損益:
$-121.24M
株価収益率:
-19.54
EPS:
-0.8141
ネットキャッシュフロー:
$-82.81M
1週間 パフォーマンス:
-4.73%
1か月 パフォーマンス:
-14.87%
6か月 パフォーマンス:
+38.59%
1年 パフォーマンス:
+157.03%
1日の値動き範囲:
$15.74
$16.47
1週間の範囲:
$15.74
$16.82
52週間の値動き範囲:
$5.975
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
名前
Adaptive Biotechnologies Corp
セクター
電話
206-659-0067
住所
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.91 | 2.48B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-09-30 | 開始されました | Guggenheim | Buy |
| 2025-06-18 | 開始されました | Craig Hallum | Buy |
| 2025-03-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-12-21 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Underperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2022-02-16 | 繰り返されました | BTIG Research | Buy |
| 2022-02-16 | 繰り返されました | BofA Securities | Buy |
| 2022-02-16 | 繰り返されました | Goldman | Neutral |
| 2022-02-16 | 繰り返されました | JP Morgan | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-03-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 開始されました | Goldman | Buy |
| 2019-07-23 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | BofA/Merrill | Buy |
| 2019-07-22 | 開始されました | Cowen | Outperform |
| 2019-07-22 | 開始されました | Goldman | Neutral |
| 2019-07-22 | 開始されました | Guggenheim | Buy |
| 2019-07-22 | 開始されました | William Blair | Outperform |
すべてを表示
Adaptive Biotechnologies Corp (ADPT) 最新ニュース
Adaptive Biotechnologies discloses it's raising $15 million for subsidiary - The Business Journals
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Adaptive Biotechnologies announces subsidiary’s Series A financing round By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CorpUnit held initial closing $15 million Series A financingSEC filing - marketscreener.com
Adaptive Biotechnologies announces subsidiary’s Series A financing round - Investing.com
Adaptive Biotechnologies Announces Series A Financing for Subsidiary - TradingView — Track All Markets
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock - Investing.com
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock By Investing.com - Investing.com UK
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle (ADPT) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Leads Life Sciences Sector with 183.57% YTD Gain - GuruFocus
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals - simplywall.st
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD (ADPT:NASDAQ) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Is Up 10.1% After New Pfizer TCR-AI Collaboration Milestone DealWhat's Changed - simplywall.st
Will Adaptive Biotechnologies Corporation stock see PE expansionTrade Risk Summary & Real-Time Market Trend Scan - Улправда
How Adaptive Biotechnologies Corporation (1HM) stock trades after rate cutsGlobal Markets & High Accuracy Trade Signal Alerts - Улправда
How Adaptive Biotechnologies Corporation stock responds to policy changesMarket Activity Recap & Fast Moving Stock Trade Plans - Улправда
First Week of February 2026 Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Why Adaptive Biotechnologies Corporation stock remains undervaluedJuly 2025 Technicals & Trade Opportunity Analysis Reports - Улправда
Adaptive Biotechnologies Insider Sold Shares Worth $1,773,267, According to a Recent SEC Filing - marketscreener.com
Adaptive Biotechnologies Exec Sells Shares Under Trading Plan - TradingView — Track All Markets
Officer Lo Sells 113,890 ($1.8M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity - Stock Titan
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer Collaborations and Surging 2024 Share Price - simplywall.st
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst - Benzinga
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com India
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Yahoo Finance
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - The Manila Times
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care - Yahoo Finance
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive B - GuruFocus
Adaptive Biotechnologies Director Sells Shares - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT) director reports sale of 22,968 shares at $16 - Stock Titan
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Dir Hershberg Files To Sell 22,968 Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - The Manila Times
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) to discuss MRD, clonoSEQ at Jefferies chat - Stock Titan
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Insider Monkey
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Seattle InnoLayoffs at Adaptive I Rover's marketing efforts - The Business Journals
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting - The Manila Times
Adaptive Biotechnologies Corp (ADPT) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):